Galmed Pharmaceuticals (NASDAQ: GLMD) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Galmed Pharmaceuticals to similar companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.
Risk and Volatility
Galmed Pharmaceuticals has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals’ competitors have a beta of 6.22, meaning that their average stock price is 522% more volatile than the S&P 500.
This table compares Galmed Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Galmed Pharmaceuticals Competitors||-5,302.67%||-356.18%||-38.99%|
This is a summary of recent ratings for Galmed Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Galmed Pharmaceuticals Competitors||846||3197||11593||230||2.71|
Galmed Pharmaceuticals presently has a consensus price target of $20.75, suggesting a potential upside of 154.91%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.82%. Given Galmed Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Galmed Pharmaceuticals is more favorable than its competitors.
Earnings & Valuation
This table compares Galmed Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Galmed Pharmaceuticals||$470,000.00||-$16.95 million||-7.33|
|Galmed Pharmaceuticals Competitors||$284.28 million||$34.29 million||135.15|
Galmed Pharmaceuticals’ competitors have higher revenue and earnings than Galmed Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
9.9% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Galmed Pharmaceuticals competitors beat Galmed Pharmaceuticals on 7 of the 12 factors compared.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company’s Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.